Skip to content
Forensic Analysis · Medical Devices · as of Nov 9, 2026

Integra Lifesciences Holdings Corp (IART)

A forensic read on Integra Lifesciences Holdings Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
1.2
Distress distance
Clean
Earnings quality
2
Forensic signals
-39.9%
ROE
1.5%
Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Integra Lifesciences Holdings Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.2, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-13.5%
FY2025
Return on invested capital. Return on invested capital is -13.5% in the latest fiscal year and slipping across FY2023–FY2025 from 2.9%. After-tax operating profit was $93M in FY2023 and ($390M) in FY2025, with operating income at 7.2% of revenue in FY2023, 1.8% in FY2024 and -30.2% in FY2025. The capital base behind it went from $3.2B in FY2023 to $2.9B in FY2025 (-10%), while the revenue it carried went from $1.5B to $1.6B. FY2025's operating profit carried a $511M goodwill write-off that alone took about 14.0 points off that year's return, so about 14.0 of the 16.4-point fall across FY2023–FY2025 is that charge landing in the latest year rather than the capital earning less. A non-cash write-down lowers the reported return in the year it lands.
$511M
FY2025
Goodwill impairments. Took $511M of goodwill writedowns across 1 year (FY2025 ($511M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$1.64B
Revenue Growth YoY+1.5%
Revenue CAGR (2yr)+3.0%
Net Margin-31.6%
Free Cash Flow-$31.1M
Return on Equity-39.9%
Debt / Equity0.70x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Integra Lifesciences Holdings Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.